Clinical Trial Detail

NCT ID NCT02435680
Title Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

triple-receptor negative breast cancer

Therapies

MCS110

Carboplatin + Gemcitabine

Age Groups: adult

No variant requirements are available.